View Exam | PowerPak

1. JZ is a 72-year-old female recently diagnosed with multiple myeloma. Her prior medical history is unremarkable except for a mild stroke 3 years ago from which she has since fully recovered. Her oncologist has prescribed a bortezomib/lenalidomide treatment regimen. All of following are appropriate potential prophylactic strategies to mitigate adverse events in JZ, EXCEPT:

A. Fluoroquinolone therapy B. Rasburicase therapy C. Fondaparinux therapy D. Acyclovir therapy

2. Which of the following treatment/adverse drug reaction pairings is CORRECT?

A. Lenalidomide/cardiotoxicity B. Imatinib/viral infections C. Rituximab/secondary malignancies D. Doxorubicin/emesis

3. Which of the following patients has the LOWEST risk for experiencing adverse events related to tyrosine kinase inhibitors?

A. A patient with a cardiac arrhythmia B. A patient receiving anticoagulation therapy C. A patient with osteoporosis D. A patient with Class A cirrhosis

4. Which of the following agents is the most appropriate for antifungal prophylaxis in a patient with acute myeloid leukemia who is receiving myelosuppressive therapy?

A. Micafungin B. Posaconazole C. Amphotericin B deoxycholate D. Fluconazole

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Which of the following treatment/adverse drug reaction pairings is CORRECT?

3. Which of the following patients has the LOWEST risk for experiencing adverse events related to tyrosine kinase inhibitors?

4. Which of the following agents is the most appropriate for antifungal prophylaxis in a patient with acute myeloid leukemia who is receiving myelosuppressive therapy?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Which of the following treatment/adverse drug reaction pairings is CORRECT?

3. Which of the following patients has the LOWEST risk for experiencing adverse events related to tyrosine kinase inhibitors?

4. Which of the following agents is the most appropriate for antifungal prophylaxis in a patient with acute myeloid leukemia who is receiving myelosuppressive therapy?

« Return to Activity

Customers who Purchased
this Activity also Purchased